28215-45-4 Usage
Uses
Used in Pharmaceutical Research and Drug Development:
2-(4-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide is employed as a key component in the discovery and development of new pharmaceuticals due to its potential biological activities. Its unique structure allows it to interact with various biological targets, making it a promising candidate for the treatment of a range of medical conditions.
Used in the Treatment of Neurological Disorders:
In the field of neurology, 2-(4-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide is used as a therapeutic agent for the treatment of neurological disorders. Its specific mode of action and interaction with neurological pathways are under investigation to determine its efficacy and safety in this application.
Used in Cancer Therapy:
2-(4-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide is also being explored for its potential use in cancer therapy. Its ability to target and affect cancer cells is currently a subject of ongoing research, with the aim of identifying its role in the treatment of various types of cancer.
Ongoing Research:
Further research is being conducted to explore the pharmacological properties and potential therapeutic uses of 2-(4-hydroxy-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide. This includes understanding its mechanism of action, optimizing its delivery methods, and assessing its safety and efficacy in treating specific medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 28215-45-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,8,2,1 and 5 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 28215-45:
(7*2)+(6*8)+(5*2)+(4*1)+(3*5)+(2*4)+(1*5)=104
104 % 10 = 4
So 28215-45-4 is a valid CAS Registry Number.
28215-45-4Relevant academic research and scientific papers
FTO INHIBITORS
-
Paragraph 081; 082; 083, (2017/01/31)
The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.
HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
-
Page/Page column 20, (2010/04/25)
Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
Benzamide derivatives and uses related thereto
-
Page/Page column 80-81, (2008/06/13)
Benzamide derivatives of formula I are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders: wherein R1, R2, R3, R4, R5, R6, R7, R8, and n are as defined herein.
